- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Guselkumab - the first selective IL-23 inhibitor for the treatment of psoriatic arthritis2023 | First Faculty of Medicine
- Risankizumab in first-line treatment of psoriasis2022 | Faculty of Medicine in Pilsen
- Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study2021 | Third Faculty of Medicine
- Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab2021 | Faculty of Medicine in Pilsen